Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis

Table 1

Basic information of included studies.

First author and year of publication	Number of subjects		Interventions		Treatment course	Baseline condition	PASI 75 (treatment group vs. control group) (case)	PASI 90 (treatment group vs. control group) (case)	PASI 100 (treatment group vs. control group) (case)	Incidence of adverse reactions (test group vs. control group) (case)
	Test group	Control group	Test group	Control group
Blauvelt et al. [14]	329	174	Guselkumab 100 mg (0 week, 4 weeks, and then 1 time/8 weeks)	Placebo	48 w	Similar	300 vs. 10	241 vs. 5	123 vs. 1	243 vs. 86
Ohtsuki et al. [17]	128	64	Guselkumab 50 mg or 100 mg (0, 4, 8 weeks, and then 1/8 weeks)	Placebo	52 w	Similar	117 vs. 4	98 vs. 0	55 vs. 0	111 vs. 36
Reich et al. [15]	496	248	Guselkumab 100 mg (0 week, 4 weeks, 8 weeks, and then 1 time/8 weeks)	Placebo	28 w	Similar	442 vs. 20	373 vs. 6	219 vs. 2	288 vs. 111
Cai at al. [19]	331	110	Secukinumab 300 mg or 150 mg (0 week, 1 week, 2 weeks, 3 weeks, and then 1 time/4 weeks)	Placebo	52 w	Similar	305 vs. 4	256 vs. 1	128 vs. 0	298 vs. 66
Gottlieb et al. [13]	361	100	Certolizumab 400 mg or 200 mg (once/2 weeks)	Placebo	48 w	Similar	287 vs. 10	176 vs. 3	—	—
Gordon et al. [18]	981	484	Briakinumab 200 mg (0 week, 3 weeks), 100 mg (8 weeks)	Placebo	52 w	Similar	792 vs. 22	604 vs. 7	316 vs. 0	517 vs. 229
Krueger et al. [12]	31	8	BI655066 intravenous or subcutaneous injection	Placebo	24 w	Similar	22 vs. 1	15 vs. 0	9 vs. 0	20 vs. 7
Reich et al. [15]	617	155	Tildrakizumab 100 mg or 200 mg (0 week, 4 weeks, 16 weeks)	Placebo	28 w	Similar	389 vs. 9	216 vs. 4	86 vs. 2	276 vs. 74
Reich et al. [15]	621	156	Tildrakizumab 100 mg or 200 mg (0 week, 4 weeks, 16 weeks)	Placebo	28 w	Similar	394 vs. 9	234 vs. 2	75 vs. 0	291 vs. 86
Reich et al. [16]	153	52	Mirikizumab 30 mg, 100 mg, 300 mg (0 week, 8 weeks)	Placebo	16 w	Similar	105 vs. 2	79 vs. 0	40 vs. 0	74 vs. 25